| Heading: |
Prostate Cancer: Screening |
| Question ID: |
1745256 |
| UIN: |
16655 |
| House: |
Commons |
| Date tabled: |
2024-11-27 |
| Asking Member ID: |
5326 |
| Asking Member display name: |
Edward Morello
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Edward Morello
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that guidance to primary care clinicians on screening for prostate cancer includes reference to the potential impact of the BRCA2 gene variation on risk levels. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
1506 |
| Answering Member display name: |
Andrew Gwynne
|
| Answering Member handle: |
GwynneMP
|
| Answering Member Twitter reference: |
@GwynneMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Prostate Cancer Risk Management Programme provides guidance for general practitioners on how to counsel men who have no symptoms but wish to have a Prostate Specific Antigen (PSA) test for prostate cancer. It highlights the potential benefits and harm... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |